Because extracellular HMGB1 is strongly associated with the clinical severity of COVID-19, leytragin-induced SIRT1 activation may contribute to the development of HMGB1-targeting therapeutics and thus to the prevention of the cytokine storms that often accompany COVID-19 [79]. The gene discussed is HMGB1; the disease is COVID-19.